[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343436-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343436-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","erk5-suppression-overcomes-fak-inhibitor-resistance-in-mutant-kras-driven-non-small-cell-lung-cancer-article-abstract","ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer - Article Abstract","","Mutated KRAS drives around 30% of non-small cell lung cancers and is linked to metastasis and therapy resistance. Focal Adhesion Kinase (FAK) sustains KRAS-driven tumors, yet clinical development of FAK inhibitors has shown limited durable anti-tumor activity. The study identifies ERK5 and CDK5 as key FAK interactors required for maintenance of KRAS mutant NSCLC. Inhibiting ERK5 and CDK5 synergistically suppresses FAK signaling, reduces proliferation, and triggers apoptosis via exacerbated ROS-induced DNA damage. Combined ERK5/CDK5 inhibition in a KrasG12D mouse model suppresses tumor progression and promotes cancer cell death, while ERK5 inhibition prevents resistance to FAK inhibitors and enhances response efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/erk5-suppression-overcomes-fak-inhibitor-resistance-in-mutant-kras-driven-non-small-cell-lung-cancer-article-abstract/343436/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/erk5-suppression-overcomes-fak-inhibitor-resistance-in-mutant-kras-driven-non-small-cell-lung-cancer-article-abstract/343436.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main problem addressed in the study?","Question",{"text":63,"@type":64},"FAK inhibitors show limited long-term anti-tumor efficacy in KRAS-driven non-small cell lung cancer, suggesting rapid resistance mechanisms.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which proteins are identified as key players underlying FAK-mediated maintenance of mutant KRAS NSCLC?",{"text":68,"@type":64},"Extracellular-signal-regulated kinase 5 (ERK5) and cyclin-dependent kinase 5 (CDK5) are revealed as FAK interactors that contribute to tumor maintenance.",{"name":70,"@type":61,"acceptedAnswer":71},"How does ERK5/CDK5 inhibition affect tumor cell behavior?",{"text":72,"@type":64},"Inhibition of ERK5 and CDK5 synergistically suppresses FAK function, decreases proliferation, and induces apoptosis through exacerbated ROS-induced DNA damage, and combined pharmacological inhibition suppresses tumor progression in a mouse model.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343436,1790178263,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article  \nERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer  \nChiara Pozzato 1, Gonçalo Outeiro-Pinho 1, Mirco Galiè2, Giorgio Ramadori 3,4 & Georgia Konstantinidou 1 ✉  \nAbstract  \nMutated KRAS serves as the oncogenic driver in 30% of non-small cell lung cancers (NSCLCs) and is associated with metastatic and therapy-resistant tumors. Focal Adhesion Kinase (FAK) acts as a mediator in sustaining KRAS-driven lung tumors, and although FAK inhibitors are currently undergoing clinical development, clinical data indicated that their efﬁcacy in producing long-term anti-tumor responses is limited. Here we revealed two FAK interactors, extracellular-signal-regulated kinase 5 (ERK5) and cyclindependent kinase 5 (CDK5), as key players underlying FAKmediated maintenance of KRAS mutant NSCLC. Inhibition of ERK5 and CDK5 synergistically suppressed FAK function, decreased proliferation and induced apoptosis owing to exacerbated ROSinduced DNA damage. Accordingly, concomitant pharmacological inhibition of ERK5 and CDK5 in a mouse model of KrasG12D-driven lung adenocarcinoma suppressed tumor progression and promoted cancer cell death. Cancer cells resistant to FAK inhibitors showed enhanced ERK5-FAK signaling dampening DNA damage. Notably, ERK5 inhibition prevented the development of resistance to FAK inhibitors, signiﬁcantly enhancing the efﬁcacy of anti-tumor responses. Therefore, we propose ERK5 inhibition as a potential co-targeting strategy to counteract FAK inhibitor resistance in NSCLC.  \nKeywords Lung Cancer; Focal Adhesions; Drug Resistance; Combination Therapy; FAK and ERK5 Inhibitors  \nSubject Categories Cancer; Respiratory System  \n[https://doi.org/10.1038/s44321-024-00138-7](https://doi.org/10.1038/s44321-024-00138-7)  \nReceived 2 November 2023; Revised 28 August 2024; Accepted 29 August 2024  \nPublished online: 13 September 2024  \nIntroduction  \nNon-small cell lung cancer (NSCLC) is the second most diagnosed cancer and the leading cause of cancer-related deaths (Siegel et al, 2021) . About 30% of NSCLCs are driven by an activating KRAS  \nmutation, which renders them aggressive and treatment resistant. Over the past years, there has been an increase in innovative targeted therapies, with the goal of improving the treatment management of patients with NSCLC. Notably, sotorasib and adagrasib have gained FDA approval for targeting KRASG12C inpatients with advanced NSCLC, providing a signiﬁcant step forward in cancer therapy (Lanman et al, 2020) . Despite these advancements, the effectiveness of these therapies remains limited, primarily attributed to drug resistance, a persistent hurdle in the landscape of targeted cancer treatments (Mohanty et al, 2023) . Therefore, the identiﬁcation of mechanisms by which cancer cells evade treatment in mutant KRAS-driven tumors is of paramount importance.  \nFAK (gene name PTK2) is a non-receptor tyrosine kinase that plays a role in regulating multiple cancer cellular functions, such as cell proliferation, migration, invasion and metastasis (Diaz Osterman et al, 2019; Lee et al, 2015; Mitra et al, 2005; Skinner et al, 2016) . Accordingly, FAK is found commonly overexpressed in invasive and metastatic cancers (Weiner et al, 1993), supporting its targeting as a valuable cancer therapeutic strategy.  \nWe previously found that FAK is required for the maintenance of KRAS mutant NSCLC. FAK inhibition in genetically engineered KRAS-driven mouse cancer models led to the regression of lung adenocarcinomas (Konstantinidou et al, 2013) . These ﬁndings, set the basis for a phase-II clinical trial with single-agent defactinib (VS-6063), an orally available ATP-competitive FAK inhibitor, in 55 heavily pretreated KRAS mutant NSCLC patients (clinical trial identiﬁer: NCT01951690) (Gerber et al, 2020) . The results of the trial were promising as defactinib provided a disease control rate (DCR) of ~50%(DCR is the % of patients whose tumor shrinks or remains stable o","cbCaigNgyOkrKWXW","https://ap.wps.com/l/cbCaigNgyOkrKWXW","pdf",6926876,25,"English","# Introduction\n## KRAS mutations and targeted therapy limitations\n## Role of FAK in KRAS mutant NSCLC\n## Rationale for investigating ERK5 and CDK5\n# Abstract\n## Key findings and proposed co-targeting strategy","[{\"question\":\"What is the main problem addressed in the study?\",\"answer\":\"FAK inhibitors show limited long-term anti-tumor efficacy in KRAS-driven non-small cell lung cancer, suggesting rapid resistance mechanisms.\"},{\"question\":\"Which proteins are identified as key players underlying FAK-mediated maintenance of mutant KRAS NSCLC?\",\"answer\":\"Extracellular-signal-regulated kinase 5 (ERK5) and cyclin-dependent kinase 5 (CDK5) are revealed as FAK interactors that contribute to tumor maintenance.\"},{\"question\":\"How does ERK5/CDK5 inhibition affect tumor cell behavior?\",\"answer\":\"Inhibition of ERK5 and CDK5 synergistically suppresses FAK function, decreases proliferation, and induces apoptosis through exacerbated ROS-induced DNA damage, and combined pharmacological inhibition suppresses tumor progression in a mouse model.\"}]","ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer - Article Abstract | PDF",1790051185,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/600afe2067bef92bf763cde22d9a52b0.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d972085b543f92dd659406137d4f6de.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b1eb7f9ac88951ad39a7a640dee045a.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04440cbb997acef2441b6b5287000f7e.webp",980,1301]